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Mutagenesis Mapping of the Protein-Protein Interaction Underlying
FusB-Type Fusidic Acid Resistance
Georgina Cox,* Thomas A. Edwards, Alex J. O’Neill
Antimicrobial Research Centre and School of Molecular and Cellular Biology, University of Leeds, Leeds, United Kingdom
FusB-type proteins represent the predominant mechanism of resistance to fusidic acid in staphylococci and act by binding to
and modulating the function of the drug target (elongation factor G [EF-G]). To gain further insight into this antibiotic resis-
tance mechanism, we sought to identify residues important for the interaction of FusB with EF-G and thereby delineate the
binding interface within the FusB–EF-G complex. Replacement with alanine of any one of four conserved residues within the
C-terminal domain of FusB (F156, K184, Y187, and F208) abrogated the ability of the protein to confer resistance to fusidic acid; the
purified mutant proteins also lost the ability to bind S. aureus EF-G in vitro. E. coli EF-G, which is not ordinarily able to bind
FusB-type proteins, was rendered competent for binding to FusB following deletion of a 3-residue tract (529SNP531) from domain
IV of the protein. This study has identified key regions of both FusB and EF-G that are important for the interaction between the
proteins, findings which corroborate our previous in silico prediction for the architecture of the complex formed between the
resistance protein and the drug target (G. Cox, G. S. Thompson, H. T. Jenkins, F. Peske, A. Savelsbergh, M. V. Rodnina, W. Win-
termeyer, S. W. Homans, T. A. Edwards, and A. J. O’Neill, Proc. Natl. Acad. Sci. U. S. A. 109:2102-2107, 2012).
The antibiotic fusidic acid (FA) is employed for the treatment ofsuperficial and systemic disease caused by staphylococci and
remains one of the few oral agents available for treating infections
caused bymethicillin-resistant Staphylococcus aureus (MRSA) (1).
FA inhibits bacterial protein synthesis through interaction with
elongation factor G (EF-G) (2, 3), a G protein responsible for
catalyzing translocation of peptidyl-tRNA from the A site to the P
site of the ribosome (4). Once translocation has occurred, EF-G
dissociates from the ribosome, vacating the A site and allowing the
next aminoacyl-tRNA species to enter the ribosome. In the pres-
ence of FA, the drug binds to EF-G and inhibits its dissociation
from the ribosome, thereby preventing further protein synthesis
and causing cessation of bacterial growth (2, 5).
Staphylococcal resistance to FA has increased considerably in
recent years, threatening the clinical utility of the drug (1, 6–9).
The predominant route to FA resistance in clinical strains of S.
aureus and other staphylococci involves horizontal acquisition of
determinants encoding FusB-type resistance proteins (6, 7, 10).
These proteins bind to EF-G and drive its release from the ribo-
some posttranslocation, even in the presence of FA (11, 12). We
recently solved the first structure of a FusB-type protein (FusC)
and broadly localized regions of both EF-G and FusB-type pro-
teins that participate in the interaction between the two binding
partners (11). The FusC crystal structure revealed a two-domain
metalloprotein, the C-terminal domain of which contains a novel
4-cysteine (C4) zinc binding fold (ZBF) that interacts with the
C-terminal domains of EF-G (11).
In the present study, we sought to gain further insight into
FusB-type proteins and their interaction with EF-G. Specifically,
we identified residues in both FusB and EF-G that participate in
the formation of the FusB–EF-G complex, thereby permitting
more precise delineation of the binding interface between this
family of resistance proteins and the drug target.
MATERIALS AND METHODS
Expression and purification of recombinant proteins. The FusB and S.
aureus EF-G proteins were expressed and purified as described previously
(11, 12). A construct for overexpression of Escherichia coli EF-G was gen-
erated by PCR amplification of fusA from E. coli JM109 (Promega, South-
ampton, United Kingdom) and ligation of this amplicon into plasmid
pET-29b (Novagen,WI,USA). Deletion of residues 529SNP531 from E. coli
EF-Gwas achieved by PCR amplification and blunt-ended ligation of two
DNA fragments of fusA flanking this region, followed by ligation into
pET-29b. E. coli EF-G was overexpressed and purified as described previ-
ously for S. aureus EF-G (11).
Alanine-scanning mutagenesis of FusB. Expression of fusB in S. au-
reus from the tetracycline-regulatable expression plasmid pAJ96 was
achieved as previously described (10). Site-directedmutagenesis of fusB in
this construct was performed by using the QuikChange II kit (Agilent
Technologies, Cheshire, United Kingdom), according to themanufactur-
er’s guidelines, and employed gel-purified oligonucleotide primers (Eu-
rofinsMWGOperon, Ebersberg, Germany). Constructs were propagated
in E. coli, followed by electroporation into S. aureusRN4220 (13).MICs of
FAwere determined by agar dilution in Iso-Sensitest agar, using inocula of
106 CFU per spot. To induce expression of fusB from the xyl/tetO pro-
moter on pAJ96, cultures were incubated with 250 ng anhydrotetracy-
cline/ml for 3 h at 37°C prior to susceptibility testing.
In vitro protein binding studies. Analytical gel filtration chromatog-
raphy was employed for in vitro analysis of binding of purified FusB mu-
tant proteins to EF-G, and eluted samples were analyzed by SDS-PAGE
(11). For binding studies, purified EF-G (2 mg) was incubated with puri-
fied FusB (10 mg) at 4°C in a final volume of 2 ml for 1 h. Samples were
applied onto a 16/60 Superdex 75 prep grade prepacked column (GE
Healthcare, Buckinghamshire, United Kingdom), eluted in running buf-
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fer (20 mM Tris-HCl [pH 8.0], 300 mM NaCl, and 1 mM dithiothreitol
[DTT]) at a flow rate of 0.5 ml/min, and analyzed by SDS-PAGE. The gel
filtration columnwas calibrated by using a low-molecular-weight calibra-
tion kit (GE Healthcare) according to the manufacturer’s guidelines, al-
lowing determination of the molecular mass of eluted proteins. Isother-
mal titration calorimetry (ITC) was performed as described previously
(11).
RESULTS
Identification of residues in FusB important for mediating in-
teraction with EF-G. In a previous study, we employed nuclear
magnetic resonance (NMR) chemical shift mapping to show that
the EF-G binding site of the FusB-type proteins lies within the
C-terminal domain of the latter (11). Tomore precisely define the
EF-G binding site, we undertook alanine-scanning mutagenesis
(14) of FusB to identify residues essential for the interaction with
EF-G. In selecting residues for mutagenesis, we focused on sur-
face-exposed residues conserved throughout the staphylococcal
family of FusB-type proteins (FusB, FusC, and FusD) (Fig. 1a),
preferentially choosing hydrophobic, aromatic, or charged amino
acids for substitution since such residues are commonly found to
participate in protein-protein interactions (PPIs) (15). We also
selected a small number of residues for substitution that we antic-
ipated would not impact the ability of FusB to bind EF-G, to act as
negative controls; these included 3 residues not conserved across
the FusB-type protein family and 2 residues lying within the N-
terminal domain of FusB (Fig. 1a).
To provide a rapid and direct screen of site-directed FusB mu-
tants for those exhibiting impaired binding to EF-G, we expressed
them in S. aureus and used susceptibility testing to identify those
mutants exhibiting increased susceptibility to FA comparedwith a
FIG 1 Alanine-scanning mutagenesis of the FusB protein. (a) Sequence alignment of staphylococcal FusB-type proteins (GenBank accession numbers
AAL12234 for FusB, YP_042173 for FusC, and YP_302255 for FusD), with residues selected for site-directed mutagenesis highlighted. Residues highlighted in
gray are substitutions that did not affect the ability of FusB to protect EF-G, while those highlighted in black correspond to substitutions that abrogated binding
of FusB to EF-G. (b) Effect of alanine-scanning mutagenesis of the FusB protein on the FA susceptibility of S. aureus RN4220(pAJ96:fusB). Amino acid
substitutions leading to reduced resistance to FA are shown in boldface type.
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strain expressing unmutagenized FusB. Of 17 amino acids in FusB
substituted for alanine (Fig. 1a), 4 (F156, K184, Y187, and F208)
caused complete, or near-complete, abrogation of the FA resis-
tance phenotype in S. aureus (Fig. 1b). Replacement with alanine
of the other conserved and surface-exposed residues (Y24, F47,
K102, K103, S127, Y145, S164, K172, and K183), residues not conserved
between FusB and FusC (T158, R190, and H194 of FusB), and resi-
dues residing within the N-terminal domain of the protein (Y24
and F47) had no effect on the ability of FusB to protect EF-G
against FA in vivo. Loss of FA resistance mediated by the four
mutant FusB proteins could have resulted from the replacement
of residues critical for the interaction with EF-G or by prompting
gross changes in the protein that prevented correct folding; the
latter seems unlikely since all four mutant proteins could be over-
expressed in E. coli and purified in a soluble form. In vitro binding
studies using analytical gel chromatography established that, in con-
trast to native FusB, none of the mutant proteins were able to bind
purified EF-G (Fig. 2).Mapping of these 4 residues onto our in silico-
predictedmodel of a FusB-type protein bound to EF-G (11) revealed
that they all reside within the anticipated binding site (Fig. 3).
Identification of a key region of EF-G responsible for medi-
ating interaction with FusB. It was previously established that
FusB-type proteins interact with the C-terminal domains (do-
mains III to V) of EF-G (11, 16); however, the precise location of
the binding site within this 35-kDa fragment is unclear. To allow
us to define key determinants of this interaction on EF-G, we
sought to understand the molecular basis for the observation that
E. coli EF-G, although exhibiting a high degree of amino acid se-
quence identity with S. aureus EF-G (60%), is unable to bind to
FusB-type proteins (11, 12). Comparison of the amino acid se-
quences of domains III to V of EF-G proteins from S. aureus
(GenBank accession number ABD29677.1) and E. coli (GenBank
accession number BAE77951.1) revealed numerous small differ-
ences between the two proteins (Fig. 4a), including an additional
3-residue tract (529SNP531) in domain IV of E. coli EF-G (Fig. 4a
and b) that is absent from the staphylococcal protein. Overlaying
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FIG 2 Analytical gel filtration chromatography to examine binding of purified FusBmutant proteins to staphylococcal EF-G. Native FusB (black line) eluted in
a complex with EF-G (100-kDa complex); the fourmutant FusB proteins (Y187A, K184A, F208A, and F156A) (25 kDa) eluted separately fromEF-G (75 kDa).
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FIG 3 Model of the interaction between FusB-type proteins and EF-G. Resi-
dues which reduced the ability of FusB to protect S. aureus from FA and
abolished binding of the protein to EF-G (F156, K184, Y187, and F208 [labeled
and colored red]) are shownmapped onto amodel of the FusC–EF-G complex
predicted in silico (11).
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E. coli EF-G onto our in silico-generated model of a FusB-type
protein bound to S. aureus EF-G (Fig. 4b) revealed that these
residues form a short loop lying within the predicted binding in-
terface (Fig. 4c), which could potentially act to prevent interaction
of FusB-type proteins with E. coli EF-G through steric hindrance.
To investigate this possibility, we deleted 529SNP531 from E. coli
EF-G and evaluated the ability of the purified mutant protein to
bind FusB. Analytical gel filtration chromatography demon-
strated that deletion of 529SNP531 rendered E. coli EF-G capable of
binding FusB in vitro (data not shown), a finding that we subse-
quently confirmed using ITC (Fig. 4d).
DISCUSSION
Since binding of FusB-type proteins to EF-G is central to FA re-
sistance (11, 12), detailed knowledge of the interaction occurring
between these proteins will be essential for gaining a more com-
plete understanding of the resistancemechanism. In this study, we
sought to mapmore precisely the binding interface between FusB
and EF-G by delineating key residues that impact binding.
Four amino acids in FusB were identified that, when substi-
tuted for alanine, abrogated binding of the protein to EF-G, both
in vivo and in vitro (Fig. 1 and 3). All four of these residues lie
within the C-terminal domain of FusB, in close proximity to the
ZBF (Fig. 3), the region of the protein that we have previously
predicted by in silico modeling to include the EF-G binding site
(11). The majority of these amino acids possess bulky hydropho-
bic side chains, which may suggest that binding of FusB-type pro-
teins to EF-G is driven by burial of surface-exposed hydrophobic
residues. We were intrigued to find that although the K184A sub-
FIG 4 A 3-residue tract (529SNP531) in domain IV of E. coli EF-G prevents the protein from binding FusB. (a) Sequence alignment of S. aureus EF-G (saEF-G)
and E. coli EF-G (ecEF-G) C-terminal domains. The additional 3-residue tract (529SNP531) present in E. coli EF-G is highlighted in red. (b) Superposition of E.
coli EF-G (dark blue) and S. aureus EF-G (green), indicating the location of 529SNP531 in E. coli EF-G (shown in red). (c) Superposition of E. coli EF-G (dark blue)
onto our previously reported model of FusC (light blue) and S. aureus EF-G (green) (11), indicating the location of the E. coli EF-G 529SNP531 loop within the
FusC–EF-G binding interface. (d) Analysis of binding of E. coli EF-G (529SNP531) to FusB by ITC. The dissociation constant (Kd) and stoichiometry of the
complex (N) are indicated.
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stitution abrogated the ability of FusB to bind EF-G and mediate
FA resistance, substitution of the adjacent residueK183 did not. An
explanation for this observation is provided by our in silico FusC–
EF-Gmodel (11), in which K183 is orientated away fromEF-G and
is not therefore anticipated to participate in the interaction be-
tween FusB-type proteins and EF-G.
We have previously localized the site of binding of FusB-type
proteins on EF-G to a region residing within domains III to V of
EF-G (11). Binding studies using FusB and hybrid E. coli-S. aureus
EF-Gproteins have further emphasized the importance of domain
IV of EF-G in the interaction with FusB-type proteins (16). Here
we have established that a 3-residue tract (529SNP531) located in
domain IV of E. coli EF-G, but which is absent from S. aureus
EF-G, is responsible for preventing binding of FusB-type proteins
to the former; deletion of this tract renders E. coli EF-G competent
for binding to FusB in vitro. These 3 residues form a short loop in
E. coli EF-G that lies close to the in silico-predicted binding site of
FusB-type proteins (11) (Fig. 4c) and likely causes steric occlusion
of FusB-type proteins from E. coli EF-G. This observation indi-
cates that FusB-type proteins are in direct contact with, or in very
close proximity to, domain IV of EF-G in the vicinity of 529SNP531.
Since this region of EF-G makes direct contact with the ribosome
(17), this observation supports our proposal that binding of FusB-
type proteins to EF-G would prevent EF-G from making normal
ribosomal contacts and that binding of EF-G to FusB-type pro-
teins and to the ribosome are mutually exclusive events (11). We
note that although deletion of 529SNP531 from E. coli EF-G is suf-
ficient to allow the protein to bind FusB, the affinity of this inter-
action (Kd [dissociation constant] of 5.8 M) (Fig. 4d) is consid-
erably lower than that observed for FusB with S. aureus EF-G (Kd
of 59 nM) (11), indicating that other amino acid differences be-
tween S. aureus and E. coli EF-G proteins must also influence the
interaction with FusB.
This study has delineated key residues within the family of
FusB-type proteins responsible for binding to EF-G and thereby
mediating resistance to FA. Given that the binding of FusB to
EF-G can be completely abrogated by substitution of a single
amino acid in the former, it is tempting to speculate that the clin-
ical activity of FA could be rejuvenated by the identification of
small-molecule inhibitors capable of blocking the PPI between
FusB-type resistance proteins and the drug target.
ACKNOWLEDGMENTS
This work was supported by research grant BB/H018433/1 and a doctoral
training grant from the Biotechnology and Biological Sciences Research
Council (United Kingdom).
REFERENCES
1. Howden BP, Grayson ML. 2006. Dumb and dumber—the potential
waste of a useful antistaphylococcal agent: emerging fusidic acid resistance
in Staphylococcus aureus. Clin. Infect. Dis. 42:394–400.
2. Bodley JW, Zieve FJ. 1969. Formation of the ribosome-G factor-GDP
complex. Biochem. Biophys. Res. Commun. 37:437–443.
3. Tanaka N, Kinoshita T, Masukawa H. 1968. Mechanism of protein
synthesis inhibition by fusidic acid and related antibiotics. Biochem. Bio-
phys. Res. Commun. 30:278–283.
4. Rodnina MV, Savelsbergh A, Katunin VI, Wintermeyer W. 1997. Hy-
drolysis of GTP by elongation factor G drives tRNA movement on the
ribosome. Nature 385:37–41.
5. Seo HS, Abedin S, Kamp D, Wilson DN, Nierhaus KH, Cooperman BS.
2006. EF-G-dependent GTPase on the ribosome, conformational change
and fusidic acid inhibition. Biochemistry 45:2504–2514.
6. McLaws FB, Larsen AR, Skov RL, Chopra I, O’Neill AJ. 2011. Distri-
bution of fusidic acid resistance determinants in methicillin-resistant
Staphylococcus aureus. Antimicrob. Agents Chemother. 55:1173–1176.
7. Castanheira M, Watters AA, Bell JM, Turnidge JD, Jones RN. 2010.
Fusidic acid resistance rates and prevalence of resistance mechanisms
among Staphylococcus spp. isolated inNorthAmerica andAustralia, 2007-
2008. Antimicrob. Agents Chemother. 54:3614–3617.
8. Castanheira M, Watters AA, Mendes RE, Farrell DJ, Jones RN. 2010.
Occurrence and molecular characterization of fusidic acid resistance
mechanisms among Staphylococcus spp. from European countries (2008).
J. Antimicrob. Chemother. 65:1353–1358.
9. O’Neill AJ, Larsen AR, Henriksen AS, Chopra I. 2004. A fusidic acid-
resistant epidemic strain of Staphylococcus aureus carries the fusB deter-
minant, whereas fusA mutations are prevalent in other resistant isolates.
Antimicrob. Agents Chemother. 48:3594–3597.
10. O’Neill AJ, McLaws F, Kahlmeter G, Henriksen AS, Chopra I. 2007.
Genetic basis of resistance to fusidic acid in staphylococci. Antimicrob.
Agents Chemother. 51:1731–1740.
11. Cox G, Thompson GS, Jenkins HT, Peske F, Savelsbergh A, Rodnina
MV, Wintermeyer W, Homans SW, Edwards TA, O’Neill AJ. 2012.
Ribosome clearance by FusB-type proteins mediates resistance to the an-
tibiotic fusidic acid. Proc. Natl. Acad. Sci. U. S. A. 109:2102–2107.
12. O’Neill AJ, Chopra I. 2006. Molecular basis of fusB-mediated resistance
to fusidic acid in Staphylococcus aureus. Mol. Microbiol. 59:664–676.
13. Fairweather N, Kennedy S, Foster TJ, Kehoe M, Dougan G. 1983.
Expression of a cloned Staphylococcus aureus alpha-hemolysin determi-
nant in Bacillus subtilis and Staphylococcus aureus. Infect. Immun. 41:
1112–1117.
14. Wells JA. 1991. Systematic mutational analyses of protein-protein inter-
faces. Methods Enzymol. 202:390–411.
15. Stites WE. 1997. Protein-protein interactions: interface structure, bind-
ing thermodynamics, andmutational analysis. Chem. Rev. 97:1233–1250.
16. Guo X, Peisker K, Backbro K, Chen Y, Koripella RK, Mandava CS,
Sanyal S, Selmer M 2012. Structure and function of FusB: an elongation
factor G-binding fusidic acid resistance protein active in ribosomal trans-
location and recycling. Open Biol. 2:120016. doi:10.1098/rsob.120016.
17. Gao YG, Selmer M, Dunham CM, Weixhlbaumer A, Kelley AC, Ra-
makrishnanV. 2009. The structure of the ribosomewith elongation factor
G trapped in the posttranslocational state. Science 326:694–699.
Cox et al.
4644 aac.asm.org Antimicrobial Agents and Chemotherapy
 o
n
 February 1, 2014 by UNIVERSITY O
F LEEDS
http://aac.asm
.org/
D
ow
nloaded from
 
